Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Accumulated Expenses (2016 - 2025)

Tg Therapeutics has reported Accumulated Expenses over the past 10 years, most recently at $21.8 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $21.8 million for Q4 2025, up 43.89% from a year ago — trailing twelve months through Dec 2025 was $21.8 million (up 43.89% YoY), and the annual figure for FY2025 was $21.8 million, up 43.89%.
  • Accumulated Expenses for Q4 2025 was $21.8 million at Tg Therapeutics, up from $15.0 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for TGTX hit a ceiling of $21.8 million in Q4 2025 and a floor of $1.6 million in Q1 2022.
  • Median Accumulated Expenses over the past 5 years was $8.4 million (2022), compared with a mean of $8.5 million.
  • Biggest five-year swings in Accumulated Expenses: soared 158.55% in 2021 and later plummeted 66.57% in 2022.
  • Tg Therapeutics' Accumulated Expenses stood at $10.2 million in 2021, then fell by 17.06% to $8.4 million in 2022, then skyrocketed by 44.35% to $12.2 million in 2023, then increased by 24.75% to $15.2 million in 2024, then surged by 43.89% to $21.8 million in 2025.
  • The last three reported values for Accumulated Expenses were $21.8 million (Q4 2025), $15.0 million (Q3 2025), and $10.6 million (Q2 2025) per Business Quant data.